Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Chemotherapy followed by Radiotherapy in Laryngeal/Hypopharyngeal Carcinoma
NCT05420597Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2021
- Primary completion
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in laryngeal cancer and hypopharyngeal cancer, sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 2 years. Started Apr 2021; status: recruiting.
02
Drugs
toripalimab
03
Conditions
laryngeal cancerhypopharyngeal cancer
Beyond the preview
Go deeper on NCT05420597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05420597.